Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

PURPOSE: To evaluate efficacy and safety of venetoclax + azacitidine among treatment-naïve patients with FLT3-mutant acute myeloid leukemia. PATIENTS AND METHODS: Data were pooled from patients enrolled in a phase III study (NCT02993523) that compared patients treated with venetoclax + azacitidine o...

Descripción completa

Detalles Bibliográficos
Autores principales: Konopleva, Marina, Thirman, Michael J., Pratz, Keith W., Garcia, Jacqueline S., Recher, Christian, Pullarkat, Vinod, Kantarjian, Hagop M., DiNardo, Courtney D., Dail, Monique, Duan, Yinghui, Chyla, Brenda, Potluri, Jalaja, Miller, Catherine L., Wei, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365380/
https://www.ncbi.nlm.nih.gov/pubmed/35063965
http://dx.doi.org/10.1158/1078-0432.CCR-21-3405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365380/
https://www.ncbi.nlm.nih.gov/pubmed/35063965
http://dx.doi.org/10.1158/1078-0432.CCR-21-3405

Ejemplares similares